159 related articles for article (PubMed ID: 9809552)
41. DNA fusion vaccines against B-cell tumors.
Zhu D; Rice J; Savelyeva N; Stevenson FK
Trends Mol Med; 2001 Dec; 7(12):566-72. PubMed ID: 11733220
[TBL] [Abstract][Full Text] [Related]
42. [Construction and expression of a prokaryotic expression plasmid of idiotypic vaccine against B cell lymphoma: encoding the fusion genes of single-chain variable fragment and MCP-3].
Wang FX; Zhao B; Cheng YH; Pan L; Luo JM; Zhang XJ; Dong ZR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1151-5. PubMed ID: 17204183
[TBL] [Abstract][Full Text] [Related]
43. Anti-CD3 single-chain Fv/interleukin-18 fusion DNA induces anti-mycobacterial resistance via efficient interferon-gamma production in BALB/c mice infected with Mycobacterium avium.
Kim SH; Cho D; Kim TS
Vaccine; 2006 Apr; 24(16):3365-73. PubMed ID: 16481075
[TBL] [Abstract][Full Text] [Related]
44. DNA vaccines against cancer: from genes to therapy.
Stevenson FK
Ann Oncol; 1999 Dec; 10(12):1413-8. PubMed ID: 10643531
[TBL] [Abstract][Full Text] [Related]
45. Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system.
Yang J; Kanter G; Voloshin A; Michel-Reydellet N; Velkeen H; Levy R; Swartz JR
Biotechnol Bioeng; 2005 Mar; 89(5):503-11. PubMed ID: 15669088
[TBL] [Abstract][Full Text] [Related]
46. Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2.
Zeytin HE; Tripathi PK; Bhattacharya-Chatterjee M; Foon KA; Chatterjee SK
Cancer Gene Ther; 2000 Nov; 7(11):1426-36. PubMed ID: 11129285
[TBL] [Abstract][Full Text] [Related]
47. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1.
Wang YS; Wang GQ; Wen YJ; Wang L; Chen XC; Chen P; Kan B; Li J; Huang C; Lu Y; Zhou Q; Xu N; Li D; Fan LY; Yi T; Wu HB; Wei YQ
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6779-87. PubMed ID: 18006780
[TBL] [Abstract][Full Text] [Related]
48. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
49. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
Leitch HA; Connors JM
Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
[TBL] [Abstract][Full Text] [Related]
50. A genetic approach to idiotypic vaccination for B cell lymphoma.
Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
[TBL] [Abstract][Full Text] [Related]
51. Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma.
Iurescia S; Fioretti D; Pierimarchi P; Signori E; Zonfrillo M; Tonon G; Fazio VM; Rinaldi M
J Biomed Biotechnol; 2010; 2010():316069. PubMed ID: 20445751
[TBL] [Abstract][Full Text] [Related]
52. Giving DNA vaccines a helping hand.
Falo LD; Storkus WJ
Nat Med; 1998 Nov; 4(11):1239-40. PubMed ID: 9809542
[No Abstract] [Full Text] [Related]
53. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines.
Hawkins RE; Zhu D; Ovecka M; Winter G; Hamblin TJ; Long A; Stevenson FK
Blood; 1994 Jun; 83(11):3279-88. PubMed ID: 8193363
[TBL] [Abstract][Full Text] [Related]
54. Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.
McCann KJ; Godeseth R; Chudley L; Mander A; Di Genova G; Lloyd-Evans P; Kerr JP; Malykh VB; Jenner MW; Orchard KH; Stevenson FK; Ottensmeier CH
Cancer Immunol Immunother; 2015 Aug; 64(8):1021-32. PubMed ID: 25982371
[TBL] [Abstract][Full Text] [Related]
55. Vaccine therapy in NHL: future promises and current limitations.
Stevenson FK; King A; Ottensmeier CH
Leuk Lymphoma; 2003; 44 Suppl 3():S85-90. PubMed ID: 15202530
[TBL] [Abstract][Full Text] [Related]
56. Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines.
Kanter G; Yang J; Voloshin A; Levy S; Swartz JR; Levy R
Blood; 2007 Apr; 109(8):3393-9. PubMed ID: 17164345
[TBL] [Abstract][Full Text] [Related]
57. Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis.
Norton PM; Brown HW; Wells JM; Macpherson AM; Wilson PW; Le Page RW
FEMS Immunol Med Microbiol; 1996 Jun; 14(2-3):167-77. PubMed ID: 8809553
[TBL] [Abstract][Full Text] [Related]
58. Cloning variable region genes of clonal lymphoma immunoglobulin for generating patient-specific idiotype DNA vaccine.
Cha SC; Qin H; Sakamaki I; Kwak L
Methods Mol Biol; 2014; 1139():289-303. PubMed ID: 24619688
[TBL] [Abstract][Full Text] [Related]
59. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions.
Biragyn A; Kwak LW
Immunol Rev; 1999 Aug; 170():115-26. PubMed ID: 10566146
[TBL] [Abstract][Full Text] [Related]
60. Idiotypic DNA vaccines against B-cell lymphoma.
Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Hawkins RE
Immunol Rev; 1995 Jun; 145():211-28. PubMed ID: 7590827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
